Recent Updates
Recently added Catalysts

Sinovac PCV13

Phase 3

Pneumococcal Infectious Disease | Biologics | Infectious Disease |Sinovac Biotech, Ltd|Trials Updated: May 18, 2026

Sinovac PCV13 development status

Highest phase Phase 3
Registered trials 3 across 2 sponsors since Dec 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials3
Total Enrollment3,720

FDA Designations

No designations recorded

Sinovac PCV13 clinical trials

Sinovac PCV13 · 3 trials · 2 indications

Phase 3 2Phase 1 1
NCT07593924Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)Pneumococcal Infectious Diseases
NOT YET_RECRUITING500 Analytics
NCT06617715Clinical Trial of 13-Valent Pneumococcal Conjugate VaccinePneumococcal Infectious Disease
RECRUITING3,080 Analytics
PHASE3NOT YET_RECRUITING
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
Pneumococcal Infectious DiseasesUnlock trial analytics
PHASE3RECRUITING
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
Pneumococcal Infectious DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
30 days after dose 2.

Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) \> -10% for each serotype at 30 days after dose 2.

Geometric mean concentrations (GMCs) of serotype-specific IgG antibody.
30 days after dose 2

Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) \> 0.5 for each serotype at 30 days after dose 2.

Proportion of pneumococcal serotype-specific IgG antibody concentration ≥0.35 μg/ml (seropositive rate)
30 days after primary vaccination

Proportion of serotype-specific IgG concentration ≥0.35 μg/ml

Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC)
30 days after primary vaccination

IgG GMC

Incidence of adverse reactions
0-30 days after each dose

Incidence of adverse reactions within 30 days after each dose

Secondary Endpoints

Percentage of participants with pneumococcal serotype-specific IgG antibody concentrations≥0.35 μg/mL .
30 days after dose 3.
Geometric mean concentrations (GMCs ) of serotype-specific IgG antibody.
30 days after dose 3.
Percentage of participants with serotype-specific IgG concentrations ≥ 1.0 μg/mL
30 days after dose 2
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Sinovac PCV 13EXPERIMENTAL250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
Prevenar 13™ACTIVE_COMPARATOR250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months.
Experimental: Sinovac PCV13EXPERIMENTALParticipants aged 6 weeks-5 years will receive 4 doses of Sinovac PCV13 according to different immunization schedules.
Active Comparator: Prevnar®ACTIVE_COMPARATORParticipants aged 6 weeks-5 years will receive 4 doses of Prevnar 13® according to different immunization schedules.
Infants aged 2 months in experimental groupEXPERIMENTAL35 participants aged 2 months will be randomized to receive Sinovac PCV13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
Infants aged 2 months in control groupACTIVE_COMPARATOR35 participants aged 2 months will be randomized to receive PREVNAR 13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months.
Children aged 2-5 years in experimental groupEXPERIMENTAL35 children aged 2-5 years will be randomized to receive Sinovac PCV13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.
Children aged 2-5 years in control groupACTIVE_COMPARATOR35 children aged 2-5 years will be randomized to receive PREVNAR 13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old.

Interventions

NameTypeDescription
Sinovac PCV13BIOLOGICALOne dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age.
Prevenar 13™BIOLOGICALOne dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age.
Prevnar®BIOLOGICALOne dose of Prevnar® (0.5 mL) is administered intramuscularly.
PREVNAR 13BIOLOGICAL0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
Unlock Study Design Details

Eligibility Criteria

Age Range42 Days to 89 Days
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Health infants aged approximately 2 months (42 to 89 days) 2. Have a parent/legal guardian who has provided written informed consent after being fully informed about the study. 3. Be able to provide the vaccination records since birth. 4. The infant's mother is tested negativ...

Countries:PhilippinesChina
Unlock Eligibility Criteria

Frequently asked questions about Sinovac PCV13

What is Sinovac PCV13?

Sinovac PCV13 is an investigational 13-valent pneumococcal conjugate vaccine being developed by Sinovac Biotech, Ltd for the prevention of pneumococcal infectious disease. It is a biologic given to healthy volunteers, including infants from about six weeks of age, and is currently in Phase 3 clinical development.

What is Sinovac PCV13 used for in pneumococcal infectious disease?

Sinovac PCV13 is being developed for pneumococcal infectious disease, the infections caused by Streptococcus pneumoniae. Its clinical trials enroll healthy volunteers, including infants as young as 42 days, and evaluate the vaccine in that pediatric population. It is investigational and has not been established as a marketed preventive vaccine.

Who is developing Sinovac PCV13?

Sinovac PCV13 is being developed by Sinovac Biotech, Ltd, which trades under the ticker SVA. The company sponsors the Phase 3 and earlier clinical trials of the 13-valent pneumococcal conjugate vaccine in infants and young children.

What phase is Sinovac PCV13 in?

Sinovac PCV13 is in Phase 3 clinical development. Two Phase 3 trials are registered, one recruiting in China and one not yet recruiting in the Philippines, alongside a completed Phase 1b trial. The vaccine remains investigational and is not approved for marketing.

What clinical trials is Sinovac PCV13 in?

Sinovac PCV13 has three registered trials. NCT06617715 is a recruiting Phase 3 trial in China with 3,080 participants. NCT07593924 is a Phase 3 trial in the Philippines with 500 infants aged 42 to 89 days that is not yet recruiting. NCT06183216 is a completed Phase 1b trial in China with 140 participants.

How are the Sinovac PCV13 trials designed?

The Sinovac PCV13 trials are randomized, double-blind, and active-controlled, enrolling healthy volunteers from six weeks of age. Across the three registered studies, total planned enrollment is 3,720 participants. The Phase 3 studies are conducted in China and the Philippines, and the Phase 1b study in China is completed.